Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| 20s Proteasome Overview | 6 | 1 |
| Therapeutics Development | 7 | 4 |
| 20s Proteasome Products under Development by Stage of Development | 7 | 1 |
| 20s Proteasome Products under Development by Therapy Area | 8 | 1 |
| 20s Proteasome Products under Development by Indication | 9 | 2 |
| 20s Proteasome Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| 20s Proteasome Products under Development by Companies | 13 | 3 |
| 20s Proteasome Therapeutics Assessment | 16 | 5 |
| Assessment by Monotherapy/Combination Products | 16 | 1 |
| Assessment by Mechanism of Action | 17 | 1 |
| Assessment by Route of Administration | 18 | 2 |
| Assessment by Molecule Type | 20 | 1 |
| 20s Proteasome Companies Involved in Therapeutics Development | 21 | 4 |
| Amgen Inc. | 21 | 2 |
| LG Life Science LTD. | 23 | 1 |
| Triphase Accelerator Corporation | 24 | 1 |
| 20s Proteasome Drug Profiles | 25 | 24 |
| carfilzomib Drug Profile | 25 | 12 |
| marizomib Drug Profile | 37 | 4 |
| oprozomib Drug Profile | 41 | 3 |
| Small Molecules to Inhibit 20S Proteasome for Multiple Myeloma and Solid Tumor Drug Profile | 44 | 1 |
| VPE-001 Drug Profile | 45 | 1 |
| VPEA-002 Drug Profile | 46 | 1 |
| VPEA-004 Drug Profile | 47 | 1 |
| VR-23 Drug Profile | 48 | 1 |
| 20s Proteasome Dormant Projects | 49 | 1 |
| 20s Proteasome Featured News &Press Releases | 50 | 18 |
| Sep 27, 2016: Amgen Announces Top-Line Results From Phase 3 KYPROLIS (Carfilzomib) CLARION Study In Newly Diagnosed Multiple Myeloma Patients | 50 | 1 |
| Sep 07, 2016: ONO Launches KYPROLIS for Intravenous Injection 10 mg and 40 mg Proteasome Inhibitor | 51 | 1 |
| Sep 07, 2016: ONO Submits Supplemental New Drug Application in Japan for KYPROLIS for Intravenous Injection 10 mg and 40 mg , a Proteasome Inhibitor, for Relapsed or Refractory Multiple Myeloma | 51 | 1 |
| Jul 04, 2016: ONO Receives Manufacturing and Marketing Approval in Japan for KYPROLIS, a Proteasome Inhibitor, in Relapsed or Refractory Multiple Myeloma | 52 | 1 |
| Jul 03, 2016: European Commission Approves Extended Indication For Amgen's Kyprolis (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma Patients | 53 | 2 |
| Jun 10, 2016: New Analyses From Pivotal Phase 3 Studies Show Kyprolis (Carfilzomib) Allows Patients With Relapsed Multiple Myeloma To Live Longer Without Disease Progression | 55 | 4 |
| Jun 09, 2016: Preliminary data for pre-kidney transplant being presented June 13 | 59 | 1 |
| Jun 06, 2016: New Phase 3 Secondary Analysis Shows Progression-Free Survival Benefit In Early Relapsing Multiple Myeloma Patients Treated With Kyprolis (Carfilzomib)-Based Regimen | 60 | 1 |
| Jun 04, 2016: Triphase Accelerator Corporation Announces Positive Results of Phase 1 Trial of Marizomib and Bevacizumab in Malignant Glioma | 61 | 1 |
| Jun 03, 2016: Amgen Announces Launch Of KYPROLIS (carfilzomib) CENTRAL, An Online News Resource Demonstrating The Impact Of Relapsed Multiple Myeloma On The Lives Of Patients And Caregivers | 62 | 1 |
| May 27, 2016: Amgen Receives Positive CHMP Opinion To Extend Indication Of Kyprolis (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma | 62 | 1 |
| May 26, 2016: Kyprolis (Carfilzomib) Demonstrates Economic Value In Relapsed Or Refractory Multiple Myeloma Manuscript Published In "Journal of Medical Economics" | 63 | 1 |
| May 19, 2016: Amgen Highlights Data on Kyprolis at 21st Congress Of The European Hematology Association | 64 | 2 |
| May 18, 2016: Amgen To Present Data on Kyprolis (carfilzomib) At ASCO 2016 | 66 | 1 |
| Apr 19, 2016: Triphase Accelerator Corporation Announces Positive Interim Results of Phase 1 Trial of Marizomib and Bevacizumab in Malignant Glioma | 67 | 1 |
| Appendix | 68 | 2 |
| Methodology | 68 | 1 |
| Coverage | 68 | 1 |
| Secondary Research | 68 | 1 |
| Primary Research | 68 | 1 |
| Expert Panel Validation | 68 | 1 |
| Contact Us | 68 | 1 |
| Disclaimer | 69 | 1 |